Use of flow cytometry for characterization of human cytomegalovirus vaccine particles

J Vlasak, VM Hoang, S Christanti, R Peluso, F Li… - Vaccine, 2016 - Elsevier
J Vlasak, VM Hoang, S Christanti, R Peluso, F Li, TD Culp
Vaccine, 2016Elsevier
Despite a 40-year effort, an effective vaccine against human cytomegalovirus (HCMV)
remains an unmet medical need. The discovery of potent neutralizing epitopes on the
pentameric gH complex (gH/gL/UL128/130/131) has reenergized HCMV vaccine
development. Our whole-virus vaccine candidate, currently in a Phase I clinical trial, is
based on the attenuated AD169 strain with restored expression of the pentameric gH
complex. Given the complexity of a whole-virus vaccine, improved analytical methods have …
Abstract
Despite a 40-year effort, an effective vaccine against human cytomegalovirus (HCMV) remains an unmet medical need. The discovery of potent neutralizing epitopes on the pentameric gH complex (gH/gL/UL128/130/131) has reenergized HCMV vaccine development. Our whole-virus vaccine candidate, currently in a Phase I clinical trial, is based on the attenuated AD169 strain with restored expression of the pentameric gH complex. Given the complexity of a whole-virus vaccine, improved analytical methods have been developed to better characterize heterogeneous viral particles released from infected cells during vaccine production. Here we show the utility of a commercial flow cytometer for the detection of individual HCMV particles, either via light scattering or using fluorescence after labeling of specific antigens. Rapid measurements requiring minimal material provide near real-time information on particle concentration, distributions of different particle types, and product purity. Additionally, utilizing immunoreagents has allowed us to characterize the distribution of key antigens across individual particles and particle types.
Elsevier